Annabel Sammy's questions to Evofem Biosciences (EVFM) leadership • Q4 2021
Question
On behalf of Annabel Sammy of Stifel, a question was asked regarding the level of copay assistance included in Q4 2021 results versus Q3. A second question probed whether the company has observed tangible benefits in access or prescription trends in early 2022 from the new zero-dollar copay guidance.
Answer
CFO Jay File explained that while the copay program was active for most of Q4, accounting for its January discontinuation positively impacted the gross-to-net calculation in December, with Q1 2022 being the first full quarter to reflect the change. CEO Saundra Pelletier confirmed that they have already seen a positive lift in access as many small and mid-sized plans have adopted the new coverage ahead of the mandate.